The use of drug-Eluting stents in acute myocardial infarction-is the battle coming to an end? From despair to acceptance;Zastosowanie stentów uwalniajacych leki w swiezym zawale serca - czy batalia dobiega konca? Od zwatpienia do aprobaty

Postepy w Kardiologii Interwencyjnej

Volumn 9, Issue 1, 2013, Pages

  Kübler, Piotr ^a   Reczuch, Krzysztof ^a,b  

^a MILITARY HOSPITAL   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute myocardial infarction; Drug eluting stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TIROFIBAN; UMIROLIMUS; ZOTAROLIMUS;

CARDIOVASCULAR RISK; DISEASE REGISTRY; DRUG EFFICACY; DRUG ELUTING STENT; FIBRINOLYSIS; HEART DEATH; HUMAN; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84876260823     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2013.34028     Document Type: Review

References (43)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: ameta-regression analysis of randomized trials. Int J Cardiol 2008; 126: 37-44.
3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
5. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
6. Tolleson TR, Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003; 92: 330-333.
7. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaksel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
8. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419.
9. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
10. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799.
11. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
12. Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924-1930.
13. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-1113.
14. Van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51: 618-626.
15. Kelbaek H, Thuesen L, Helquist S, et al. Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Nyocardial Infarction (DEDICATION) trial. Circulation 2008; 118: 1155-1162.
16. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drugeluting versus bare-metal stent implantation in patients with STelevation myocardial infarction: 3-year follow-up of the randomized DEDICATION trial. J Am Coll Cardiol 2010; 56: 641-645.
17. Boden H, van der Hoeven BL, Liem SS, et al. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. Eurointervention 2011; 7: 1021-1029.
18. Vink MA, Dirksen MT, Suttorp MJ, et al. 5-Year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction. J Am Coll Cardiol Int 2011; 4: 24-29.
19. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
20. Stone GW, Parise H, Witzenbichler B, et al. Selection criteria for drugeluting versus bare-metal stents and the impact of routine angiographic follow-up 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2010; 56: 1597-1604.
21. Sabate M, Cequier A, Iniguez A, et al. Rationale and design of the EXAMINATION trial: a randomised comparison between everolimuseluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. Eurointervention 2011; 7: 977-984.
22. Raber L, Kelbaek H, Ostoijc M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction. The COMFORTABLE AMI randomized trial. JAMA 2012; 308: 777-787.
23. Hofma SH, Brouwer J, Velders MA, et al. Second-generation eve-rolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. J Am Coll Cardiol 2012; 60: 381-387.
24. Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011; 7: 936-943.
25. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 1370-1376.
26. Guagliumi G, Sirbu V, Bezerra H, et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC Cardiovasc Interv 2010; 3: 680-687.
27. Pasceri V, Patti G, Speciale G, et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 2007; 153: 749-754.
28. Dibra A, Tiroch K, Schulz S, et al. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol 2010; 99: 345-357.
29. Piscione F, Piccolo R, Cassese S, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomized trials and an adjusted indirect comparison. Eurointervention 2010; 5: 853-860.
30. Brar S, Leon M, Stone G et al. Use of drug-eluting stents in acute myocardial infarction. A systematic review and meta-analysis. J Am Coll Cardiol 2009; 53: 1677-1689.
31. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting versus baremetal stents in primary angioplasty. A pooled patient-level metaanalysis of randomized trials. Arch Intern Med 2012; 172: 611-621.
32. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 977-987.
33. Lemos PA, Saia F, Hofman SH, et al. Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004; 43: 704-708.
34. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of threeyear clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99: 1027-1032.
35. Steg PG, Fox KA, Eagle KA, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-329.
36. Brodie B, Pokharel Y, Fleishman N, et al. Very late stent thrombosis after primary percutaneous coronary intervention with baremetal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. J Am Coll Cardiol Int 2011; 4: 30-38.
37. Hannan EL, Racz M, Walford G, et al. Drug-eluting versus bare metal stents in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol Int 2008; 1: 129-135.
38. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359: 1330-1342.
39. Kübler P, Jankowska EA, Ferenc M, et al. Comparison of drug-eluting stents to bare-metal stents in ST-elevation myocardial infarction in long-term follow-up. Kardiol Pol 2013; 71: 25-31.
40. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
41. Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241.
42. Witkowski A, Opolski M, Dudek D, et al. Current status of drug-eluting stents and drug-eluting balloons in patients with stable coronary artery disease: an expert consensus document of the Association for Percutaneous Cardiovascular Interventions and the Polish Cardiac Society. Postep Kardiol Inter 2011; 7: 20-55.
43. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264.